1,009 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
PFE Pfizer, Inc. $43.01 $252.13B N/A
Article Searches
Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma http://www.zacks.com/stock/news/524596/mercks-keytruda-combo-gets-fda-nod-for-endometrial-carcinoma?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-524596 Sep 18, 2019 - Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.
Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert http://www.zacks.com/stock/news/520833/breast-cancer-drugs-may-inflame-lungs-per-fda-safety-alert?cid=CS-ZC-FT-analyst_blog|industry_focus-520833 Sep 16, 2019 - The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.
Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others http://www.zacks.com/stock/news/516828/pharma-stock-roundup-pipeline-regulatory-updates-from-gsk-pfe-others?cid=CS-ZC-FT-analyst_blog|stock_roundup-516828 Sep 13, 2019 - Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
Renal Cell Carcinoma Space in Focus: Some Key Developments http://www.zacks.com/stock/news/516791/renal-cell-carcinoma-space-in-focus-some-key-developments?cid=CS-ZC-FT-analyst_blog|industry_focus-516791 Sep 13, 2019 - The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
4 Big Drugmakers Boasting Impressive Oncology Pipelines http://www.zacks.com/stock/news/513001/4-big-drugmakers-boasting-impressive-oncology-pipelines?cid=CS-ZC-FT-analyst_blog|industry_focus-513001 Sep 11, 2019 - We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class? https://www.fool.com/investing/2019/09/05/is-the-fda-out-to-get-this-29-billion-diabetes-dru.aspx?source=iedfolrf0000001 Sep 05, 2019 - It’s rejected a pair of drugs in the last six months.
J&J's Stelara Gets Approval in EU for Ulcerative Colitis http://www.zacks.com/stock/news/503348/jjs-stelara-gets-approval-in-eu-for-ulcerative-colitis?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-503348 Sep 05, 2019 - Johnson & Johnson (JNJ) receives European Commission's (EC) approval for the label expansion of Stelara for the treatment of adults with moderately-to-severely active ulcerative colitis (UC).
Merck's Keytruda Combination Gets EC Nod for Kidney Cancer http://www.zacks.com/stock/news/503040/mercks-keytruda-combination-gets-ec-nod-for-kidney-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-503040 Sep 05, 2019 - Merck's (MRK) label expansion application for Keytruda in combination with Pfizer's Inlyta for the first-line treatment of renal cell carcinoma gets approval in Europe.
Global Blood Focuses on Lead Candidate Amid Competition http://www.zacks.com/stock/news/499644/global-blood-focuses-on-lead-candidate-amid-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-499644 Sep 03, 2019 - Global Blood (GBT) focuses on the development of its lead product candidate, voxelotor - an oral, once-daily treatment for SCD.
Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More http://www.zacks.com/stock/news/453588/busy-morning-for-investors-trade-data-earnings-for-pfe-mrk-cop-more?cid=CS-ZC-FT-ahead_of_wall_street-453588 Jul 30, 2019 - Another busy day awaits investors here in the middle of summer: U.S.-China trade talks resume, Personal Income & Spending data is out and Q2 earnings continue their torrent.

Pages: 123456...101

Page 1>